Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | SWOG S1823: miR-371 as a biomarker for in early-stage testicular cancer

Lucia Nappi, MD, University of British Columbia, Vancouver, Canada, presents first interim analysis results from the SWOG S1823 trial (NCT04435756), assessing the operating characteristics of circulating microRNA 371a-3p (miR371) in detecting tumor relapse in patients with early-stage active germ cell malignancy managed with active surveillance. Results demonstrated high specificity and negative predictive value for miR371, supporting its potential clinical utility in surveillance and future interventional trial integration for germ cell tumors. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Germ cell tumors patients are unique because they are very young. Indeed, germ cell tumors are the most common solid tumors in young men. And most of them are diagnosed with early stage disease because we don’t have very good reliable biomarker to predict relapse. Most of these patients are followed on active surveillance. The active surveillance is mainly based on cross-sectional imaging, mainly CT scans and serum tumor markers that have limited accuracy to detect early relapse...

Germ cell tumors patients are unique because they are very young. Indeed, germ cell tumors are the most common solid tumors in young men. And most of them are diagnosed with early stage disease because we don’t have very good reliable biomarker to predict relapse. Most of these patients are followed on active surveillance. The active surveillance is mainly based on cross-sectional imaging, mainly CT scans and serum tumor markers that have limited accuracy to detect early relapse. So CT scan and serum tumor markers have limited sensitivity and specificity, especially in early stage disease, and there’s more so in seminoma than in non-seminoma. Moreover, we are exposing patients to the radiation from the CT scans when we use this kind of active surveillance tools. On the other hand, a biomarker like microRNA371 is highly specific for non-seminoma and seminoma germ cell tumors. It is not expressed by teratoma, which is a subgroup of non-seminoma. And all the retrospective studies and few prospective studies have demonstrated high accuracy to detect germ cell tumors. The first interim analysis I presented at ASCO 2026 in 224 patients, 69 relapses and 155 non-relapses in patients have shown very high specificity, 94%, high negative predictive value, 90%. Well, the sensitivity was lower than specificity, but it increased with stage at the relapse. Moreover, another important finding of our study was that if we do measure microRNA 371 at baseline, post-orchiectomy, the patients with a post-orchiectomy microRNA 371 positive result in a significantly shorter relapse-free survival compared to the patients who are negative immediately post-orchiectomy, with a hazard ratio of 9.9 that was very highly statistically significant.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...